Heart failure

Drugs for the Heart: Expert Consult - Online and Print

Volumn , Issue , 2013, Pages 169-223

  Teerlink, John R ^a,b   Sliwa, Karen ^c,d   Opie, Lionel H ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899478724     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-3322-4.00015-6     Document Type: Chapter

References (349)

1. Editorial Lancet 378 2011 637.
2. Felker GM., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward Circ Heart Fail 3 2010 314-325.
3. Metra M., et al. The pathophysiology of acute heart failure-it is a lot about fluid accumulation Am Heart J 155 2008 1-5.
4. Peacock WF., et al.Morphine and outcomes in acute decompensated heart failure an ADHERE analysis Emer Med J 25 2008 205-209.
5. Felker GM., et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 2011 797-805.
6. Yilmaz MB., et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis Eur J Heart Fail 13 2011 1244-1252.
7. Damman K., et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease J Am Coll Cardiol 53 2009 582-588.
8. Mullens W., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure J Am Coll Cardiol 53 2009 589-596.
9. Cotter G., et al. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation Eur J Heart Fail 10 2008 165-169.
10. Fallick C., et al.Sympathetically mediated changes in capacitance redistribution of the venous reservoir as a cause of decompensation Circ Heart Fail 4 2011 669-675.
11. Mebazaa A., et al.Short-term survival by treatment among patients hospitalized with acute heart failure the global ALARM-HF registry using propensity scoring methods Intensive Care Med 37 2011 290-301.
12. Giamouzis G., et al.Impact of dopamine infusion on renal function in hospitalized heart failure patients results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) trial J Card Fail 16 2010 922-930.
13. Elkayam U., et al.Renal vasodilatory action of dopamine in patients with heart failure magnitude of effect and site of action Circulation 117 2008 200-205.
14. de Lissovoy G., et al.Hospital costs for treatment of acute heart failure economic analysis of the REVIVE II study Eur J Health Econ 11 2010 185-193.
15. Teerlink JR., et al.Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil a first-in-man study Lancet 378 2011 667-675.
16. Cleland JG., et al.The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 2011 676-683.
17. Hasenfuss G., et al.Cardiac inotropes current agents and future directions Eur Heart J 32 2011 1838-1845.
18. Mullens W., et al. Sodium nitroprusside for advanced low-output heart failure J Am Coll Cardiol 52 2008 200-207.
19. Ezekowitz JA., et al.Assessment of dyspnea in acute decompensated heart failure insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow J Am Coll Cardiol 59 2012 1441-1448.
20. O’Connor CM., et al. Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32-43.
21. Teerlink JR., et al.Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF) a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study Lancet 373 2009 1429-1439.
22. Ponikowski P., et al. Design of the RELAXin in acute heart failure study Am Heart J 163 2012 149-155.
23. Bauer SR., et al. Arginine vasopressin for the treatment of septic shock in adults Pharmacotherapy 30 2010 1057-1071.
24. Gassanov N., et al. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH) Eur J Clin Pharm 67 2011 333-346.
25. Elzouki AN., et al.Terlipressin-induced severe left and right ventricular dysfunction in patient presented with upper gastrointestinal bleeding case report and literature review Am J Emer Med 28 2010 540.
26. Narayen G., Mandal SN., et al. Vasopressin receptor antagonists and their role in clinical medicine Indian J Endocrinol Metab 16 2012 183-191.
27. Gross PA., et al.Vaptans are not the mainstay of treatment in hyponatremia perhaps not yet Kidney Int 80 2011 594-600.
28. Udelson JE., et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction J Card Fail 17 2011 973-981.
29. Howell NJ., et al.Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial Circulation 123 2011 170-177.
30. Milo-Cotter O., et al.Neurohormonal activation in acute heart failure results from VERITAS Cardiology 119 2011 96-105.
31. Homma S., et al. For the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm N Engl J Med 366 2012 1859-1869.
32. O’Connor CM., et al. For the HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial JAMA 301 2009 1439-1450.
33. Flynn KE., et al.Effects of exercise training on health status in patients with chronic heart failure HF-ACTION randomized controlled trial JAMA 301 2009 1451-1459.
34. Angermann CE., et al.on behalf of the Competence Network Heart Failure Mode of Action and Effects of Standardized Collaborative Disease Management on Mortality and Morbidity in Patients With Systolic Heart Failure the Interdisciplinary Network for Heart Failure (INH) Study Circ Heart Fail 5 2012 25-35.
35. Funck-Brentano C., et al. CIBIS-III investigators. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial Eur J Heart Fail 13 2011 765-772.
36. Castagno D., et al.Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure results from the CHARM (Candesartan in Heart Failureassessment of Reduction in Mortality and morbidity) program J Am Coll Cardiol 59 2012 1785-1795.
37. Swedberg K., et al.Ivabradine and outcomes in chronic heart failure (SHIFT) a randomised placebo-controlled study Lancet 376 2010 875-885 Erratum in Lancet 2010;376:1988.
38. Teerlink JR Ivabradine in heart failure-no paradigm SHIFT yet Lancet 376 2010 847-849.
39. Swedberg K., et al.Effect on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure is there an influence of beta-blocker dose J Am Coll Cardiol 59 2012 1785-1795.
40. Ekman I., et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study Eur Heart J 32 2011 2395-2404.
41. Böhm M., et al.Heart rate as a risk factor in chronic heart failure (SHIFT) the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 376 2010 886-894.
42. Volterrani M., et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial) Int J Cardiol 151 2011 218-224.
43. Konstam MARenal function and heart failure treatment when is a loss really a gain Circ Heart Fail 4 2011 677-679.
44. Rossignol P., et al.Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy J Am Coll Cardiol 58 2011 1958-1966 58.
45. Zannad F., et al. for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11-21.
46. Cleland JG., et al.Clinical trials update from the ESC Heart Failure meeting 2011 TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF Eur J Heart Fail 13 2011 1147-1151.
47. Rossignol P., et al.Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Circulation 125 2012 271-279.
48. Dai W., et al. Is inhibition of phosphodiesterase Type 5 by sildenafil a promising therapy for volume-overload heart failure Circulation 125 2012 1341-1343.
49. Schwartz BG., et al. Cardiac uses of phosphodiesterase-5 inhibitors J Am Coll Cardiol 59 2012 9-15.
50. Swedberg K., et al.The beat goes on on the importance of heart rate in chronic heart failure Eur Heart J 33 2012 1044-1045.
51. Talajic M., et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation J Am Coll Cardiol 55 2010 1796-1802.
52. Phan TT., et al.Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina old drug, new hope Eur J Heart Fail 11 2009 881-886.
53. Tuunanen H., et al. Effects of trimetazidine, a metabolic modulator, on cardiac function and substrate metabolism in idiopathic cardiomyopathy 2008 Circulation [Submitted].
54. Zhang L., et al.Additional use of trimetazidine in patients with chronic heart failure a meta-analysis J Am Coll Cardiol 59 2012 913-922.
55. McMurray JJ., et al. Calcium handling in the failing heart and SUMO-weighing the evidence N Engl J Med 365 2011 1738-1739.
56. Jessup M., et al. For the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID)a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure Circulation 124 2011 304-313.
57. Kho C., et al. SUMO1-dependent modulation of SERCA2a in heart failure Nature 477 2011 601-605.
58. Bolli R., et al.Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO) initial results of a randomised phase 1 trial Lancet 378 2011 1847-1857.
59. Makkar RR., et al.Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS) a prospective, randomised phase 1 trial Lancet 379 2012 895-904.
60. Ghali JK., et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia Circulation 117 2008 526-535.
61. Skali H., et al.TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience Circulation 124 2011 2903-2908.
62. McMurray JJ., et al.RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF) a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail 11 2009 795-801.
63. Anker SD., et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2009 2436-2448.
64. Comin-Colet J., et al.The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency a subanalysis of the FAIR-HF study Jan 31, 2012 Eur Heart J.
65. Jones RHCoronary bypass surgery with or without surgical ventricular reconstruction STICH Hypothesis 2 Investigators N Engl J Med 360 2009 1705-1717.
66. Velazquez EJ., et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction N Engl J Med 364 2011 1607-1616.
67. Bonow RO., et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction N Engl J Med 364 2011 1617-1625.
68. Slaughter MS., et al. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device N Engl J Med 361 2009 2241-2251.
69. Strueber M., et al. HeartWare Investigators. Multicenter evaluation of an intrapericardial left ventricular assist system J Am Coll Cardiol 57 2011 1375-1382.
70. Kirklin JK., et al.Third INTERMACS Annual Report the evolution of destination therapy in the United States J Heart Lung Transplant 30 2011 115-123.
71. Opie LH Dilated cardiomyopathy and potentially deadly digoxin S Afr Med J 101 2011 388-390.
72. Arispe N., et al. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels Proc Nat Acad Sci USA 105 2008 2610-2615.
73. Opie LH., et al. Dronaderone in high-risk permanent atrial fibrillation New Engl J Med 366 2012 1159.
74. Jessup M., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 1977-2016.
75. Ahmed A., et al.Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure a propensity-matched study of the DIG trial Int J Cardiol 123 2008 138-146.
76. Georgiopoulou VV., et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy Circ Heart Fail 2 2009 90-97.
77. Biggar RJ., et al. Digoxin use and the risk of breast cancer in women J Clin Oncol 29 2011 2165-2170.
78. Ahren TP., et al.Digoxin treatment is associated with an increased incidence of breast cancer a population-based case-control study Breast Cancer Res 10 2008 R102.
79. Yukawa M., et al.Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy a population pharmacokinetics analysis using nonlinear mixed-effects modelling Drugs Aging 28 2011 831-841.
80. Nordt SP., et al. Retrospective review of digoxin exposures to a poison control system following recall of Digitek® tablets Am J Cardiovasc Drugs 10 2010 261-263.
81. Pita-Fernández S., et al. Clinical manifestations of elderly patients with digitalis intoxication in the emergency department Arch Gerontol Geriatr 53 2011 e106-e110.
82. Desai AS., et al. The TOPCAT study. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction Am Heart J 162 2011 966-972.
83. van Veldhuisen DJ., et al.Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol 53 2009 2150-2158.
84. Vogel MW., et al.The natural history of preclinical diastolic dysfunction a population-based study Circ Heart Fail 5 2012 144-151.
85. Gaasch WH., et al.Left ventricular structural remodeling in health and disease with special emphasis on volume, mass, and geometry J Am Coll Cardiol 58 2011 1733-1740.
86. Deswal A., et al. Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF) J Card Fail 17 2011 634-642.
87. Kitzman DWOutcomes in patients with heart failure with preserved ejection fraction it is more than the heart J Am Coll Cardiol 59 2012 1006-1007.
88. Sliwa K., et al. Hypertension-a global perspective Circulation 123 2011 2892-2896.
89. Stewart S., et al.The clinical consequences and challenges of hypertension in urban-dwelling black Africans insights from the Heart of Soweto Study Int J Cardiol 146 2011 22-27.
90. Carlsen MC., et al.Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide a 10-year analysis from the Copenhagen Hospital Heart Failure Study Eur J Heart Failure 14 2012 240-247.
91. Holland DJ., et al.Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction a meta-analysis J Am Coll Cardiol 57 2011 1676-1686.
92. Ariti CA., et al.Days alive and out of hospital and the patient journey in patients with heart failure insights from the candesartan in heart failureassessment of reduction in mortality and morbidity (CHARM) program Am Heart J 162 2011 900-906.
93. Massie BM., et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2008 2456-2467.
94. Anand IS., et al.Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction findings from the I-PRESERVE trial Circ Heart Fail 4 2011 569-577.
95. Sabatine MS., et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease Circulation 125 2012 233-240.
96. Edelmann F., et al.Rationale and design of the aldosterone receptor blockade in diastolic heart failure trial a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF) Eur J Heart Fail 12 2010 874-882.
97. Solomon SD., et al.for the PARAMOUNT Investigators.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387-1395.
98. Ruilope LM., et al.Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255-1266.
99. Schwartzenberg S., et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy J Am Coll Cardiol 59 2012 442-451.
100. Azevedo PS., et al. Predictors of right ventricle dysfunction after anterior myocardial infarction Mar 13, 2012 Can J Cardiol [Epub ahead of print].
101. Sayer GT., et al. Right ventricular performance in chronic congestive heart failure Cardiol Clin 30 2012 271-282.
102. Haddad F., et al. Right ventricular function in cardiovascular disease. Part I. Anatomy, physiology, aging and functional assessment of the right ventricle Circulation 117 2008 1436-1448.
103. Haddad F., et al.Right ventricular function in cardiovascular disease. Part II pathophysiology, clinical importance, and management of right ventricular failure Circulation 117 2008 1717-1731.
104. De Man FS., et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension Circ Heart Fail 5 2012 97-105.
105. Bogaard HJ., et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats Am J Respir Crit Care Med 182 2010 652-660.
106. Van de Veerdonk MC., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy J Am Coll Cardiol 58 2011 2511-2519.
107. Damy T., et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure Eur Heart J 31 2010 2280-2290.
108. Rosenkranz S., et al.Pulmonary hypertension due to left heart disease updated Recommendations of the Cologne Consensus Conference 2011 Int J Cardiol 154 Suppl 1 2011 S34-S44.
109. Bishu K., et al. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo Circulation 124 2011 2882-2891.
110. Archer SL., et al. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension N Engl J Med 361 2009 1864-1871.
111. Archer SL., et al.Basic science of pulmonary arterial hypertension for clinicians new concepts and experimental therapies Circulation 121 2010 2045-2066.
112. Sweiss NJ., et al. Diagnosis and management of pulmonary hypertension in systemic sclerosis Curr Rheumatol Rep 12 2010 8-18.
113. Macchia A., et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed Am Heart J 159 2010 245-257.
114. Stevens GR., et al. RV dysfunction in pulmonary hypertension is independently related to pulmonary artery stiffness JACC Cardiovasc Imaging 5 2012 378-387.
115. Galiè N., et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394-403.
116. Zisman DA., et al.Idiopathic Pulmonary Fibrosis Clinical Research Network a controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis N Engl J Med 363 2010 620-628.
117. Iglarz M., et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist J Pharmacol Exp Ther 327 2008 736-745.
118. Levin J April 30, 2012 SERAPHIN trial, Actelion Release [Available on Google].
119. Simonneau G., et al.PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension a randomized trial Ann Intern Med 149 2008 521-530.
120. Yanagisawa R., et al. Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension Circ J 76 2012 1245-1252.
121. Waxman AB., et al. Cicletanine for the treatment of pulmonary arterial hypertension Arch Intern Med 168 2008 2164-2166.
122. Mouchaers KT., et al.Fasudil reduces monocrotaline-induced pulmonary arterial hypertension comparison with bosentan and sildenafil Eur Respir J 36 2010 800-807.
123. Kwapiszewska G., et al. PAR-2 Inhibition reverses experimental pulmonary hypertension Circ Res 110 2012 1179-1191.
124. Geschka S., et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats PLoS One 6 2011 e218-e253.
125. Simonneau G., et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension Eur Respir J 40 2012 874-880.
126. Kekewska A., et al. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells J Pharmacol Exp Ther 340 2012 369-376.
127. Campo A., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension Am J Respir Crit Care Med 182 2010 252-260.
128. Yao W., et al. Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells Pulm Circ 1 2012 405-418.
129. Montani D., et al. Pulmonary arterial hypertension in patients treated by dasatinib Circulation 125 2012 2128-2137.
130. Cabassi A., et al. Eplerenone use in primary aldosteronism during pregnancy Hypertension 59 2012 e18-e19.
131. Regitz-Zagrosek A., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy Eur Heart J 32 2011 3147-3197.
132. Bhattacharyya A., et al.Peripartum cardiomyopathy a review Tex Heart Inst J 39 2012 8-16.
133. Biteker M., et al.Delayed recovery in peripartum cardiomyopathy an indication for long-term follow-up and sustained therapy Eur J Heart Fail 14 2012 895-901.
134. Sliwa K., et al.Current status on knowledge on aetiology, diagnosis, management, and therapy on peripartum cardiomyopathy a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy Eur J Heart Fail 12 2010 767-778.
135. Sliwa K., et al.Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy a proof of concept pilot study Circulation 121 2010 1465-1473.
136. Lewis T Diseases of the Heart 1933 Macmillan London.
137. Editorial Lancet 378 2011 637.
138. Felker GM., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward Circ Heart Fail 3 2010 314-325.
139. Metra M., et al. The pathophysiology of acute heart failure-it is a lot about fluid accumulation Am Heart J 155 2008 1-5.
140. Nohria A., et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure J Am Coll Cardiol 41 2003 1797-1804.
141. Meine TJ., et al.Association of intravenous morphine use and outcomes in acute coronary syndromes results from the CRUSADE Quality Improvement Initiative Am Heart J 149 2005 1043-1049.
142. Peacock WF., et al.Morphine and outcomes in acute decompensated heart failure an ADHERE analysis Emer Med J 25 2008 205-209.
143. Felker GM., et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 2011 797-805.
144. Yilmaz MB., et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis Eur J Heart Fail 13 2011 1244-1252.
145. Eshaghian S., et al. Relation of loop diuretic dose to mortality in advanced heart failure Am J Cardiol 97 2006 1759-1764.
146. Damman K., et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease J Am Coll Cardiol 53 2009 582-588.
147. Mullens W., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure J Am Coll Cardiol 53 2009 589-596.
148. Cotter G., et al. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation Eur J Heart Fail 10 2008 165-169.
149. Fallick C., et al.Sympathetically mediated changes in capacitance redistribution of the venous reservoir as a cause of decompensation Circ Heart Fail 4 2011 669-675.
150. Cotter G., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema Lancet 351 1998 389-393.
151. Mebazaa A., et al.Short-term survival by treatment among patients hospitalized with acute heart failure the global ALARM-HF registry using propensity scoring methods Intensive Care Med 37 2011 290-301.
152. Nieminen MS., et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 384-416.
153. Abraham WT., et al.In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 2005 57-64.
154. Böhm M., et al.Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial Crit Care Med 39 2011 940-944.
155. O’Connor CM., et al.Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J 138 1999 78-86.
156. Al-Hesayen A., et al. The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure J Am Coll Cardiol 39 2002 1269-1274.
157. Galley HFRenal-dose dopamine will the message now get through Lancet 356 2000 2112.
158. Giamouzis G., et al.Impact of dopamine infusion on renal function in hospitalized heart failure patients results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) trial J Card Fail 16 2010 922-930.
159. Elkayam U., et al.Renal vasodilatory action of dopamine in patients with heart failure magnitude of effect and site of action Circulation 117 2008 200-205.
160. Johnson R Low-dose dopamine and oxygen transport by the lung Circulation 98 1998 97-99.
161. Gare M., et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography J Am Coll Cardiol 34 1999 1682-1688.
162. Packer M., et al. Consensus recommendations for the management of chronic heart failure Am J Cardiol 83 2A 1999 1A-38A.
163. Annane D., et al. Use of pressors in the management of septic shock-Authors’ reply Lancet 370 2007 1827-1828.
164. Follath F., et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) a randomised double-blind trial Lancet 360 2002 196-202.
165. Mebazaa A., et al.Levosimendan vs dobutamine for patients with acute decompensated heart failure the SURVIVE Randomized trial JAMA 297 2007 1883-1891.
166. de Lissovoy G., et al.Hospital costs for treatment of acute heart failure economic analysis of the REVIVE II study Eur J Health Econ 11 2010 185-193.
167. Opie LH Inodilators Lancet 1 1986 1336.
168. Stemple DR., et al.Combined nitroprusside-dopamine therapy in severe chronic congestive heart failure dose-related hemodynamic advantages over single drug infusions Am J Cardiol 42 1978 267-275.
169. Bayram M., et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes Am J Cardiol 96 2005 47G-58G.
170. DiBianco R., et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure N Engl J Med 320 1989 677-683.
171. PROMISE Study Packer M., et al. Effect of oral milrinone on mortality in severe chronic heart failure N Engl J Med 325 1991 1468-1475.
172. Cuffe MS., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure JAMA 287 2002 1541-1547.
173. Felker GM., et al.Heart failure etiology and response to milrinone in decompensated heart failure results from the OPTIME-CHF study J Am Coll Cardiol 41 2003 997-1003.
174. Cowley AJ., et al. On behalf of the Enoximome Investigators. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone Br Heart J 72 1994 226-230.
175. Teerlink JR., et al.Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil a first-in-man study Lancet 378 2011 667-675.
176. Cleland JG., et al.The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 2011 676-683.
177. Hasenfuss G., et al.Cardiac inotropes current agents and future directions Eur Heart J 32 2011 1838-1845.
178. Robin ED., et al.Nitroprusside-related cyanide poisoning time (long past due) for urgent, effective interventions Chest 102 1992 1842-1845.
179. Mullens W., et al. Sodium nitroprusside for advanced low-output heart failure J Am Coll Cardiol 52 2008 200-207.
180. Khot UN., et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis N Engl J Med 348 2003 1756-1763.
181. Calderone A., et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes J Clin Invest 101 1998 812-818.
182. VMAC Investigators Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure JAMA 287 2002 1531-1540.
183. Elkayam U., et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure Am J Cardiol 93 2004 237-240.
184. Ezekowitz JA., et al.Assessment of dyspnea in acute decompensated heart failure insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow J Am Coll Cardiol 59 2012 1441-1448.
185. Sackner-Bernstein JD., et al. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 2005 1487-1491.
186. Sackner-Bernstein JD., et al.Short-term risk of death after treatment with nesiritide for decompensated heart failure a pooled analysis of randomized controlled trials JAMA 293 2005 1900-1905.
187. O’Connor CM., et al. Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32-43.
188. Teerlink JR., et al.Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF) a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study Lancet 373 2009 1429-1439.
189. Ponikowski P., et al. Design of the RELAXin in acute heart failure study Am Heart J 163 2012 149-155.
190. Bauer SR., et al. Arginine vasopressin for the treatment of septic shock in adults Pharmacotherapy 30 2010 1057-1071.
191. Treschan TA., et al.The vasopressin system physiology and clinical strategies Anesthesiol 105 2006 599-612.
192. Gassanov N., et al. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH) Eur J Clin Pharm 67 2011 333-346.
193. Elzouki AN., et al.Terlipressin-induced severe left and right ventricular dysfunction in patient presented with upper gastrointestinal bleeding case report and literature review Am J Emer Med 28 2010 540.
194. Narayen G., Mandal SN., et al. Vasopressin receptor antagonists and their role in clinical medicine Indian J Endocrinol Metab 16 2012 183-191.
195. Gross PA., et al.Vaptans are not the mainstay of treatment in hyponatremia perhaps not yet Kidney Int 80 2011 594-600.
196. Schrier RW., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2006 2099-2112.
197. Udelson JE., et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction J Card Fail 17 2011 973-981.
198. Gheorghiade M., et al.Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure the EVEREST Clinical Status Trials JAMA 297 2007 1332-1343.
199. Konstam MA., et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure the EVEREST Outcome Trial JAMA 297 2007 1319-1331.
200. Howell NJ., et al.Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial Circulation 123 2011 170-177.
201. Milo-Cotter O., et al.Neurohormonal activation in acute heart failure results from VERITAS Cardiology 119 2011 96-105.
202. Homma S., et al. For the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm N Engl J Med 366 2012 1859-1869.
203. ExTraMATCH Collaborative Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH) Br Med J 328 2004 189.
204. O’Connor CM., et al. For the HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial JAMA 301 2009 1439-1450.
205. Flynn KE., et al.Effects of exercise training on health status in patients with chronic heart failure HF-ACTION randomized controlled trial JAMA 301 2009 1451-1459.
206. Stewart S., et al.Effects of a multidisciplinary, home based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure a randomised controlled study Lancet 354 1999 1077-1083.
207. Angermann CE., et al.on behalf of the Competence Network Heart Failure Mode of Action and Effects of Standardized Collaborative Disease Management on Mortality and Morbidity in Patients With Systolic Heart Failure the Interdisciplinary Network for Heart Failure (INH) Study Circ Heart Fail 5 2012 25-35.
208. O’Meara E., et al.Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure results of the Candesartan in Heart Failureassessment of Reduction in Mortality and Morbidity (CHARM) Program Circulation 113 2006 986-994.
209. Elkayam U., et al. The challenge of correcting volume overload in hospitalized patients with decompensated heart failure J Am Coll Cardiol 49 2007 684-686.
210. Brater D Pharmacology of diuretics Am J Med Sci 319 2000 38-50.
211. Funck-Brentano C., et al. CIBIS-III investigators. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial Eur J Heart Fail 13 2011 765-772.
212. Willenheimer R., et al.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation 112 2005 2426-2435.
213. Flather MD., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215-225.
214. Krum H., et al.Effects of initiating carvedilol in patients with severe chronic heart failure results from the COPERNICUS Study JAMA 289 2003 712-718.
215. Ko DT., et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction JAMA 288 2002 351-357.
216. Poole-Wilson PA., et al.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) randomised controlled trial Lancet 362 2003 7-13.
217. Dandona P., et al. Antioxidant activity of carvedilol in cardiovascular disease J Hypertens 25 2007 731-741.
218. Packer M., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation 100 1999 2312-2318.
219. Castagno D., et al.Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure results from the CHARM (Candesartan in Heart Failureassessment of Reduction in Mortality and morbidity) program J Am Coll Cardiol 59 2012 1785-1795.
220. Swedberg K., et al.Ivabradine and outcomes in chronic heart failure (SHIFT) a randomised placebo-controlled study Lancet 376 2010 875-885 Erratum in Lancet 2010;376:1988.
221. Teerlink JR Ivabradine in heart failure-no paradigm SHIFT yet Lancet 376 2010 847-849.
222. Swedberg K., et al.Effect on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure is there an influence of beta-blocker dose J Am Coll Cardiol 59 2012 1785-1795.
223. Ekman I., et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study Eur Heart J 32 2011 2395-2404.
224. Böhm M., et al.Heart rate as a risk factor in chronic heart failure (SHIFT) the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 376 2010 886-894.
225. Volterrani M., et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial) Int J Cardiol 151 2011 218-224.
226. Konstam MARenal function and heart failure treatment when is a loss really a gain Circ Heart Fail 4 2011 677-679.
227. Pitt B., et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709-717.
228. Pitt B., et al. EPHESUS trial. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309-1321.
229. Rossignol P., et al.Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy J Am Coll Cardiol 58 2011 1958-1966 58.
230. Zannad F., et al. for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11-21.
231. Cleland JG., et al.Clinical trials update from the ESC Heart Failure meeting 2011 TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF Eur J Heart Fail 13 2011 1147-1151.
232. Rossignol P., et al.Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Circulation 125 2012 271-279.
233. Cohn JN., et al.Valsartan Heart Failure Trial Investigators a randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667-1675.
234. Granger CB., et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors the CHARM-Alternative trial Lancet 362 2003 772-776.
235. McMurray JJV., et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors the CHARM-Added trial Lancet 362 2003 767-771.
236. Taylor AL., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. African-American Heart Failure Trial Investigators N Engl J Med 351 2004 2049-2057.
237. Dai W., et al. Is inhibition of phosphodiesterase Type 5 by sildenafil a promising therapy for volume-overload heart failure Circulation 125 2012 1341-1343.
238. Schwartz BG., et al. Cardiac uses of phosphodiesterase-5 inhibitors J Am Coll Cardiol 59 2012 9-15.
239. Swedberg K., et al.The beat goes on on the importance of heart rate in chronic heart failure Eur Heart J 33 2012 1044-1045.
240. Talajic M., et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation J Am Coll Cardiol 55 2010 1796-1802.
241. Lee L., et al.Metabolic modulation with perhexiline in chronic heart failure a randomized, controlled trial of short-term use of a novel treatment Circulation 112 2005 3280-3288.
242. Phan TT., et al.Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina old drug, new hope Eur J Heart Fail 11 2009 881-886.
243. Tuunanen H., et al. Effects of trimetazidine, a metabolic modulator, on cardiac function and substrate metabolism in idiopathic cardiomyopathy 2008 Circulation [Submitted].
244. Fragasso G., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure J Am Coll Cardiol 48 2006 992-998.
245. Zhang L., et al.Additional use of trimetazidine in patients with chronic heart failure a meta-analysis J Am Coll Cardiol 59 2012 913-922.
246. Sliwa K., et al.Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline results of a randomized study Circulation 109 2004 750-755.
247. McMurray JJ., et al. Calcium handling in the failing heart and SUMO-weighing the evidence N Engl J Med 365 2011 1738-1739.
248. Jessup M., et al. For the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID)a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure Circulation 124 2011 304-313.
249. Kho C., et al. SUMO1-dependent modulation of SERCA2a in heart failure Nature 477 2011 601-605.
250. Bolli R., et al.Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO) initial results of a randomised phase 1 trial Lancet 378 2011 1847-1857.
251. Makkar RR., et al.Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS) a prospective, randomised phase 1 trial Lancet 379 2012 895-904.
252. Ghali JK., et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia Circulation 117 2008 526-535.
253. Skali H., et al.TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience Circulation 124 2011 2903-2908.
254. McMurray JJ., et al.RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF) a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail 11 2009 795-801.
255. Anker SD., et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2009 2436-2448.
256. Comin-Colet J., et al.The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency a subanalysis of the FAIR-HF study Jan 31, 2012 Eur Heart J.
257. Jones RHCoronary bypass surgery with or without surgical ventricular reconstruction STICH Hypothesis 2 Investigators N Engl J Med 360 2009 1705-1717.
258. Velazquez EJ., et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction N Engl J Med 364 2011 1607-1616.
259. Bonow RO., et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction N Engl J Med 364 2011 1617-1625.
260. Costanzo MR., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 2007 675-683.
261. Slaughter MS., et al. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device N Engl J Med 361 2009 2241-2251.
262. Strueber M., et al. HeartWare Investigators. Multicenter evaluation of an intrapericardial left ventricular assist system J Am Coll Cardiol 57 2011 1375-1382.
263. Kirklin JK., et al.Third INTERMACS Annual Report the evolution of destination therapy in the United States J Heart Lung Transplant 30 2011 115-123.
264. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 1997 525-533.
265. Opie LH Dilated cardiomyopathy and potentially deadly digoxin S Afr Med J 101 2011 388-390.
266. Eichhorn EJ., et al. Digoxin-new perspective on an old drug N Engl J Med 347 2002 1394-1395.
267. Hauptman P., et al. Digitalis Circulation 99 1999 1265-1270.
268. Slatton M., et al. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm J Am Coll Cardiol 29 1997 1206-1213.
269. Arispe N., et al. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels Proc Nat Acad Sci USA 105 2008 2610-2615.
270. Opie LH., et al. Dronaderone in high-risk permanent atrial fibrillation New Engl J Med 366 2012 1159.
271. Khand AU., et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure J Am Coll Cardiol 42 2003 1944-1951.
272. Rathore SS., et al. Association of serum digoxin concentration and outcomes in patients with heart failure JAMA 289 2003 871-878.
273. Jessup M., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 1977-2016.
274. Ahmed A., et al.Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure a propensity-matched study of the DIG trial Int J Cardiol 123 2008 138-146.
275. Georgiopoulou VV., et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy Circ Heart Fail 2 2009 90-97.
276. Rathore SS., et al. Sex-based differences in the effect of digoxin for the treatment of heart failure N Engl J Med 347 2002 1403-1411.
277. Biggar RJ., et al. Digoxin use and the risk of breast cancer in women J Clin Oncol 29 2011 2165-2170.
278. Ahren TP., et al.Digoxin treatment is associated with an increased incidence of breast cancer a population-based case-control study Breast Cancer Res 10 2008 R102.
279. Yukawa M., et al.Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy a population pharmacokinetics analysis using nonlinear mixed-effects modelling Drugs Aging 28 2011 831-841.
280. Nordt SP., et al. Retrospective review of digoxin exposures to a poison control system following recall of Digitek® tablets Am J Cardiovasc Drugs 10 2010 261-263.
281. Pita-Fernández S., et al. Clinical manifestations of elderly patients with digitalis intoxication in the emergency department Arch Gerontol Geriatr 53 2011 e106-e110.
282. Owan TE., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction N Engl J Med 355 2006 251-259.
283. Desai AS., et al. The TOPCAT study. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction Am Heart J 162 2011 966-972.
284. Yusuf S., et al.Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction the CHARM-Preserved trial Lancet 362 2003 777-781.
285. van Veldhuisen DJ., et al.Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol 53 2009 2150-2158.
286. Bhatia RS., et al. Outcome of heart failure with preserved ejection fraction in a population-based study N Engl J Med 355 2006 260-269.
287. Nishimura RA., et al.Understanding “diastolic heart failure” the tip of the iceberg J Am Coll Cardiol 49 2007 695-697.
288. Vogel MW., et al.The natural history of preclinical diastolic dysfunction a population-based study Circ Heart Fail 5 2012 144-151.
289. Persson H., et al. For the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES J Am Coll Cardiol 49 2007 687-694.
290. Zile MR., et al. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle N Engl J Med 350 2004 1953-1959.
291. Gaasch WH., et al.Left ventricular structural remodeling in health and disease with special emphasis on volume, mass, and geometry J Am Coll Cardiol 58 2011 1733-1740.
292. Deswal A., et al. Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF) J Card Fail 17 2011 634-642.
293. Kitzman DWOutcomes in patients with heart failure with preserved ejection fraction it is more than the heart J Am Coll Cardiol 59 2012 1006-1007.
294. Sliwa K., et al. Hypertension-a global perspective Circulation 123 2011 2892-2896.
295. Stewart S., et al.The clinical consequences and challenges of hypertension in urban-dwelling black Africans insights from the Heart of Soweto Study Int J Cardiol 146 2011 22-27.
296. Carlsen MC., et al.Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide a 10-year analysis from the Copenhagen Hospital Heart Failure Study Eur J Heart Failure 14 2012 240-247.
297. Holland DJ., et al.Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction a meta-analysis J Am Coll Cardiol 57 2011 1676-1686.
298. Ariti CA., et al.Days alive and out of hospital and the patient journey in patients with heart failure insights from the candesartan in heart failureassessment of reduction in mortality and morbidity (CHARM) program Am Heart J 162 2011 900-906.
299. Massie BM., et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2008 2456-2467.
300. Anand IS., et al.Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction findings from the I-PRESERVE trial Circ Heart Fail 4 2011 569-577.
301. Braunwald E., et al. PEACE Trial Investigators Angiotensin-converting enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058-2068.
302. Sabatine MS., et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease Circulation 125 2012 233-240.
303. Cleland JG., et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 2006 2338-2345.
304. Edelmann F., et al.Rationale and design of the aldosterone receptor blockade in diastolic heart failure trial a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF) Eur J Heart Fail 12 2010 874-882.
305. Solomon SD., et al.for the PARAMOUNT Investigators.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387-1395.
306. Ruilope LM., et al.Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255-1266.
307. Schwartzenberg S., et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy J Am Coll Cardiol 59 2012 442-451.
308. Azevedo PS., et al. Predictors of right ventricle dysfunction after anterior myocardial infarction Mar 13, 2012 Can J Cardiol [Epub ahead of print].
309. Sayer GT., et al. Right ventricular performance in chronic congestive heart failure Cardiol Clin 30 2012 271-282.
310. Haddad F., et al. Right ventricular function in cardiovascular disease. Part I. Anatomy, physiology, aging and functional assessment of the right ventricle Circulation 117 2008 1436-1448.
311. Haddad F., et al.Right ventricular function in cardiovascular disease. Part II pathophysiology, clinical importance, and management of right ventricular failure Circulation 117 2008 1717-1731.
312. De Man FS., et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension Circ Heart Fail 5 2012 97-105.
313. Bogaard HJ., et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats Am J Respir Crit Care Med 182 2010 652-660.
314. Van de Veerdonk MC., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy J Am Coll Cardiol 58 2011 2511-2519.
315. Lewis GD., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension Circulation 116 2007 1555-1562.
316. Damy T., et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure Eur Heart J 31 2010 2280-2290.
317. Rosenkranz S., et al.Pulmonary hypertension due to left heart disease updated Recommendations of the Cologne Consensus Conference 2011 Int J Cardiol 154 Suppl 1 2011 S34-S44.
318. Bishu K., et al. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo Circulation 124 2011 2882-2891.
319. Archer SL., et al. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension N Engl J Med 361 2009 1864-1871.
320. Archer SL., et al.Basic science of pulmonary arterial hypertension for clinicians new concepts and experimental therapies Circulation 121 2010 2045-2066.
321. Sweiss NJ., et al. Diagnosis and management of pulmonary hypertension in systemic sclerosis Curr Rheumatol Rep 12 2010 8-18.
322. Macchia A., et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed Am Heart J 159 2010 245-257.
323. Stevens GR., et al. RV dysfunction in pulmonary hypertension is independently related to pulmonary artery stiffness JACC Cardiovasc Imaging 5 2012 378-387.
324. Galiè N., et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394-403.
325. Barst RJ., et al.A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension the Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296-302.
326. Zisman DA., et al.Idiopathic Pulmonary Fibrosis Clinical Research Network a controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis N Engl J Med 363 2010 620-628.
327. Girgis RE., et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the sclero-derma spectrum of diseases J Heart Lung Transplant 24 2005 1626-1631.
328. Iglarz M., et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist J Pharmacol Exp Ther 327 2008 736-745.
329. Levin J April 30, 2012 SERAPHIN trial, Actelion Release [Available on Google].
330. Simonneau G., et al.PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension a randomized trial Ann Intern Med 149 2008 521-530.
331. Yanagisawa R., et al. Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension Circ J 76 2012 1245-1252.
332. Waxman AB., et al. Cicletanine for the treatment of pulmonary arterial hypertension Arch Intern Med 168 2008 2164-2166.
333. Mouchaers KT., et al.Fasudil reduces monocrotaline-induced pulmonary arterial hypertension comparison with bosentan and sildenafil Eur Respir J 36 2010 800-807.
334. Kwapiszewska G., et al. PAR-2 Inhibition reverses experimental pulmonary hypertension Circ Res 110 2012 1179-1191.
335. Geschka S., et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats PLoS One 6 2011 e218-e253.
336. Simonneau G., et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension Eur Respir J 40 2012 874-880.
337. Kekewska A., et al. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells J Pharmacol Exp Ther 340 2012 369-376.
338. Campo A., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension Am J Respir Crit Care Med 182 2010 252-260.
339. Yao W., et al. Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells Pulm Circ 1 2012 405-418.
340. Montani D., et al. Pulmonary arterial hypertension in patients treated by dasatinib Circulation 125 2012 2128-2137.
341. Cabassi A., et al. Eplerenone use in primary aldosteronism during pregnancy Hypertension 59 2012 e18-e19.
342. Regitz-Zagrosek A., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy Eur Heart J 32 2011 3147-3197.
343. Bhattacharyya A., et al.Peripartum cardiomyopathy a review Tex Heart Inst J 39 2012 8-16.
344. Biteker M., et al.Delayed recovery in peripartum cardiomyopathy an indication for long-term follow-up and sustained therapy Eur J Heart Fail 14 2012 895-901.
345. Sliwa K., et al.Current status on knowledge on aetiology, diagnosis, management, and therapy on peripartum cardiomyopathy a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy Eur J Heart Fail 12 2010 767-778.
346. Hilfiker-Kleiner D., et al. A cathepsin D-cleaved 16kDa form of prolactin mediates postpartum cardiomyopathy Cell 128 2007 589-600.
347. Bozkurt B., et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy J Am Coll Cardiol 34 1999 177-180.
348. Sliwa K., et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy Eur J Heart Fail 4 2002 305-309.
349. Sliwa K., et al.Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy a proof of concept pilot study Circulation 121 2010 1465-1473.